Rigorous accreditation process helps ensure high-quality care, ongoing process improvement and optimal outcomes CARY, N.C. (June 27, 2017) —Biologics, Inc., a McKesson Specialty Health oncology pharmacy services company, has achieved Specialty Pharmacy accreditation...
CARY, N.C. (March 28, 2017) —Biologics, Inc., a McKesson Specialty Health oncology pharmacy services company, has been selected by EMD Serono to be a specialty pharmacy provider for BAVENCIO (avelumab). Approved by the U.S. Food and Drug Administration (FDA) on March...
CARY, NC — February 1, 2016 — Biologics, Inc. has been selected by TESARO, Inc. as the exclusive specialty pharmacy provider for VARUBI™ (rolapitant), the company is pleased to announce. VARUBI was approved by the U.S. Food and Drug Administration on September 1,...
CARY, NC — November 30, 2015 — Biologics, Inc., is pleased to announce that it has been selected by Lilly Oncology as the exclusive specialty pharmacy provider for PORTRAZZA™ (necitumumab). In addition to accessing the drug via specialty distribution, Eli Lilly will...
CARY, NC — February 5, 2015 — Biologics, an integrated oncology services company, is pleased to announce that Biologics has been selected as a specialty pharmacy authorized to dispense Ibrance (palbociclib). Ibrance was approved by the U.S. Food and Drug...
CARY, NC — December 12, 2014 — Biologics, a specialty pharmacy provider for Jakafi (ruxolitinib), is pleased to announce the U.S. Food and Drug Administration has approved Jakafi to treat patients with polycythemia vera (a chronic type of bone marrow disease) who have...